Stoke Therapeutics STOK
$26.81 −$0.12 (-0.45%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.40 +2.20%
Open$26.39
Prev close$26.93
Day range$25.94 – $27.78
Volume615.8K
Market cap$1.75B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$11.26M+5.9% YoY
Operating profit-$77.32M-79.4% YoY
Net profit-$73.64M-92.0% YoY
Diluted EPS-$1.08-66.2% YoY
Free cash flow-$65.54M-114.9% YoY
Operating cash flow-$62.69M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-913.2%
Net margin-862.1%
Return on equity-73.6%
Return on assets-63.4%
Return on invested capital-73.2%
Current ratio7.24
Liabilities / assets13.3%
Cash & investments$319.19M
Net cash (debt)$319.19M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $11.26M | $9.33M | $6.23M | $184.42M | $1.40M |
| Total Operating Revenue | $11.26M | $9.33M | $6.23M | $184.42M | $1.40M |
| Operating Expense | $88.57M | $74.75M | $59.65M | $205.01M | $62.84M |
| Selling and Admin Expenses | $28.74M | $25.25M | $19.97M | $67.09M | $21.15M |
| Research & Development | $59.83M | $49.50M | $39.67M | $137.92M | $41.70M |
| Operating Profit | -$77.32M | -$65.43M | -$53.42M | -$20.59M | -$61.44M |
| Net Non-Operating Interest Income (Expense) | $3.67M | $3.50M | $3.40M | $13.76M | $3.62M |
| Total Other Finance Costs | -$3.67M | -$3.50M | -$3.40M | -$13.76M | -$3.62M |
| Other Income (Expense) | $6,000.00 | $308,000.00 | $18,000.00 | -$51,000.00 | -$110,000.00 |
| Other Non-Operating Income (Expenses) | $6,000.00 | $308,000.00 | $18,000.00 | -$51,000.00 | -$110,000.00 |
| Pretax Profit | -$73.64M | -$61.62M | -$50.00M | -$6.89M | -$57.93M |
| Tax | $0.00 | $0.00 | $0.00 | – | – |
| Net Profit | -$73.64M | -$61.62M | -$50.00M | -$6.89M | -$57.93M |
| Profit from Continuing Operations | -$73.64M | -$61.62M | -$50.00M | -$6.89M | -$57.93M |
| Net Income to Parent Company | -$73.64M | -$61.62M | -$50.00M | -$6.89M | -$57.93M |
| Net Income to Common Stockholders | -$73.64M | -$61.62M | -$50.00M | -$6.89M | -$57.93M |
| Basic EPS | -$1.08 | -$0.93 | -$0.79 | -$0.12 | -$1.00 |
| Diluted EPS | -$1.08 | -$0.93 | -$0.79 | -$0.12 | -$1.00 |
| -General & Admin Expense | – | $25.25M | $19.97M | $67.09M | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $406.69M | $393.97M | $443.28M | $418.43M | $418.43M |
| Total Current Assets | $354.42M | $322.54M | $366.68M | $305.70M | $305.70M |
| Cash and Cash Equivalents & Short-Term Investments | $319.19M | $292.82M | $343.55M | $284.67M | $284.67M |
| -Cash and Cash Equivalents | $107.27M | $110.00M | $155.66M | $84.22M | $84.22M |
| -Short Term Investments | $211.92M | $182.81M | $187.89M | $200.45M | $200.45M |
| Receivables | $10.08M | $8.72M | $6.14M | $7.91M | $7.91M |
| -Accounts Receivable | $8.54M | $7.18M | $4.45M | $5.94M | $5.94M |
| -Accrued Interest Receivable | $1.53M | $1.54M | $1.69M | $1.97M | $1.97M |
| Prepaid Assets | $17.60M | $14.69M | $10.12M | $8.74M | $8.74M |
| Other Current Assets | $7.56M | $5.82M | $6.39M | $3.90M | $3.90M |
| Total Non-Current Assets | $52.28M | $71.43M | $76.60M | $112.73M | $112.73M |
| Net PPE | $9.45M | $6.70M | $5.89M | $6.25M | $6.25M |
| -Gross PPE | $9.45M | $6.70M | $5.89M | $16.39M | $16.39M |
| Investments and Advances | $39.60M | $61.50M | $67.48M | $106.26M | $106.26M |
| -Available for Sale Securities | $39.60M | $61.50M | $67.48M | $106.26M | $106.26M |
| Other Non-Current Assets | $3.23M | $3.23M | $3.23M | $227,000.00 | $227,000.00 |
| Total Liabilities | $54.10M | $48.42M | $48.40M | $65.98M | $65.98M |
| Total Current Liabilities | $48.98M | $41.93M | $40.81M | $57.88M | $57.88M |
| Payables | $4.03M | $4.79M | $6.84M | $4.94M | $4.94M |
| -Accounts Payable | $4.03M | $4.79M | $6.84M | $4.94M | $4.94M |
| Current Accrued Expenses | $25.42M | $18.49M | $16.89M | $22.99M | $22.99M |
| Short-Term Debt and Capital Lease Obligation | $1.24M | $1.85M | $2.43M | $3.01M | $3.01M |
| -Current Capital Lease Obligation | $1.24M | $1.85M | $2.43M | $3.01M | $3.01M |
| Current Deferred Liabilities | $6.36M | $8.52M | $10.07M | $11.90M | $11.90M |
| Other Current Liabilities | $1.75M | $1.62M | $1.50M | $1.06M | $1.06M |
| Total Non-Current Liabilities | $5.13M | $6.49M | $7.59M | $8.10M | $8.10M |
| Non-Current Deferred Liabilities | $4.45M | $5.65M | $6.60M | $6.96M | $6.96M |
| Other Non-Current Liabilities | $681,000.00 | $837,000.00 | $991,000.00 | $1.14M | $1.14M |
| Total Equity | $352.59M | $345.55M | $394.88M | $352.46M | $352.46M |
| Stockholders' Equity | $352.59M | $345.55M | $394.88M | $352.46M | $352.46M |
| Capital Stock | $6,000.00 | $6,000.00 | $6,000.00 | $5,000.00 | $5,000.00 |
| -Common Stock | $6,000.00 | $6,000.00 | $6,000.00 | $5,000.00 | $5,000.00 |
| Additional Paid-In Capital | $1.04B | $955.42M | $942.70M | $849.62M | $849.62M |
| Retained Earnings | -$682.98M | -$609.34M | -$547.72M | -$497.72M | -$497.72M |
| Gains/Losses Not Affecting Retained Earnings | -$1.05M | -$542,000.00 | -$115,000.00 | $543,000.00 | $543,000.00 |
| Restricted Cash | – | $494,000.00 | $494,000.00 | $494,000.00 | $494,000.00 |
| -Accumulated Depreciation | – | – | – | -$10.15M | -$10.15M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$62.69M | -$56.59M | -$60.58M | $45.59M | -$30.45M |
| Net cash flow from continuing operations | -$62.69M | -$56.59M | -$60.58M | $45.59M | -$30.45M |
| Net Income from Continuing Operations | -$73.64M | -$61.62M | -$50.00M | -$6.89M | -$57.93M |
| Depreciation & Depletion & Amortization | $455,000.00 | $458,000.00 | $439,000.00 | $1.77M | $405,000.00 |
| Other Non-Cash Items | $637,000.00 | $680,000.00 | $608,000.00 | $2.41M | $650,000.00 |
| Change in Working Capital | -$816,000.00 | -$6.54M | -$20.01M | $16.35M | $16.98M |
| -Change in Receivables | -$1.36M | -$2.73M | $1.49M | -$4.27M | $3.31M |
| -Change in Prepaid Assets | -$4.15M | -$3.91M | -$3.59M | -$545,000.00 | $220,000.00 |
| -Change in Payables and Accrued Expense | $8.06M | $2.60M | -$15.72M | $21.29M | $8.90M |
| -Change In Other Working Capital | -$3.36M | -$2.49M | -$2.19M | -$130,000.00 | $4.54M |
| Net cash flow from investing | -$10.21M | $9.02M | $50.69M | -$186.81M | -$61.06M |
| Net Cash Flow from Continuing Investing Activities | -$10.21M | $9.02M | $50.69M | -$186.81M | -$61.06M |
| Net PPE Purchase and Sale | -$2.85M | -$1.98M | -$353,000.00 | -$670,000.00 | -$232,000.00 |
| Net Investment Purchase and Sale | -$7.36M | $10.99M | $51.05M | -$186.14M | -$60.83M |
| Financing Cash Flow | $70.16M | $1.91M | $84.33M | $97.39M | $92.34M |
| Net Cash Flow from Continuing Financing Activities | $70.16M | $1.91M | $84.33M | $97.39M | $92.34M |
| Net Common Stock Issuance | $65.70M | $0.00 | $80.66M | $87.78M | $87.78M |
| Proceeds from Stock Option Exercised | $4.47M | $1.91M | $3.67M | $9.61M | $4.56M |
| Ending Cash Balance | $110.99M | $113.73M | $159.38M | $84.94M | $84.94M |
| Net Change in Cash | -$2.73M | -$45.66M | $74.44M | -$43.84M | $826,000.00 |
| Beginning Cash Balance | $113.73M | $159.38M | $84.94M | $128.78M | $84.12M |
| Free Cash Flow | -$65.54M | -$58.56M | -$60.94M | $44.92M | -$30.69M |
| Gain/Loss from Continuing Operations | – | – | – | $145,000.00 | $153,000.00 |
No comments yet — be the first to weigh in on STOK.
Sign in to join the discussion.